Press release
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
- Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO -
About this update from Incyte Corporation
[{"type":"text","content":"\n- Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO\n\n\n- Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion\n\n\n- Julian Baker elected Chairman of the Board of Directors\n\n\n WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today announced that the Company’s Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company’s Board of Directors, effective immediately.\n\n\nBill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a member of the Board through the end of the year to ensure a smooth transition. In addition, Lead Independent Director Julian Baker has been elected Chairman of the Board of Directors.\n\n\nMr. Meury is a proven enterprise leader with expertise in organizational strategy, pipeline and commercial execution and capital allocation. He most recently served as CEO of Anthos Therapeutics, where he successfully scaled the company for its next stage of growth. Prior to that, he was CEO of Karuna Therapeutics, leading its transition into a fully integrated R&D and commercial organization. Before Karuna, Mr. Meury spent more than two decades at Allergan, serving as Chief Commercial Officer, managing a global business with fifty products, $16 billion in revenue and approximately 8,000 employees across a range of therapeutic areas.\n\n\n“I am honored to join Incyte at this pivotal moment and thank Hervé for his support during this transition,” said Mr. Meury. “Incyte's track record for discovering innovative treatments for complex problems in human health is outstanding. My priority is to build upon our exceptional R&D and commercial capabilities to accelerate new product flow, drive sustainable growth and create value for all stakeholders. I look forward to working with the Incyte team to continue to grow the company for enduring success.”\n\n\n\"Bill is a decisive and collaborative leader who possesses the strategic planning and executional skills necessary to accelerate Incyte’s growth and maximize the tremendous opportunities we have in oncology and immunology,\" said Mr. Baker. “During our thoughtful...